Treasury Unlikely to Block Pfizer-Allergan Deal

Instead of a tax inversion, the deal is "much more like a straightforward acquisition by a foreign company of a U.S. company," said Larry Harding, who heads corporate development activities for Radius, a Boston-based company that helps U.S. firms deal with financial, tax, compliance and other logistics of operating overseas.

"There's no U.S. legislation that would override a foreign company's purchases," said Harding.

Read Full Article »
Comment
Show commentsHide Comments

Related Articles